The Global Health Body Raises Concern Over Severe Scarcity of Obesity Jabs

Under a tenth of patients that would benefit from weight-loss injections like Wegovy are able to get them, states the World Health Organization as it publishes its first recommendations on the medications.

Given over a billion individuals worldwide now living with obesity, it is urging increased and just access to these injectable treatments.

According to forecasts, over two billion will be living with obesity by 2030 without intervention.

"Our new guidance recognises that excess weight is a chronic disease that can be treated with thorough and continuous treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.

High costs, insufficient output, and distribution challenges are key obstacles to widespread availability to the jabs that can assist patients in reducing substantial weight, explains the organization.

Skinny Jab Supply Crisis

Even in the current most optimistic outlook, the production of GLP-1 therapies might only reach approximately 100 million people – fewer than 10% of the global need, as stated by the health organization.

The advice urges nations and manufacturers to widen availability, by measures such as voluntary licensing.

Exclusive production rights on semaglutide – the core ingredient of the drug Wegovy – is scheduled to end in several nations in 2026.

The Way Obesity Jabs Function

These medications replicate a natural hormone to reduce digestion speed, curb appetite and enhance satiety so users reduce food intake.

Individuals typically see weight reduction in the initial weeks of commencing the regular doses.

Studies points to patients may see weight return a year later of halting the treatment, when their typical hunger resume.

To be overweight or obese raises your likelihood for developing diseases, including diabetes, heart disease, brain attack, and certain malignancies.

Excess weight impacts people in countries worldwide and was linked to over three and a half million fatalities worldwide in 2024, according to the health agency.